4820 Emperor Boulevard
689 articles with IQVIA
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Adopted by More than 30 Life Sciences Companies in First Year of Launch
IQVIA™ (NYSE:IQV) today announced that more than 30 life sciences companies have selected Orchestrated Customer Engagement (OCE) as their commercial solution in the 12 months since the groundbreaking technology first launched
IQVIA’s Innovative Technology, Advanced Analytics and Industry Expertise Demonstrate the Value of Its CORE to Industry Partners
IQVIA Holdings Inc. announced today the pricing of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC at a price to the public of $124.25 per share
IQVIA Announces on November 29, 2018 the Launch of Secondary Public Offering and Repurchase of Common Stock
IQVIA Holdings Inc. announced today the launch of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”).
IQVIA™ (NYSE:IQV) today announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ innovative commercial solutions suite, to support Napo’s growing commercial organization and enable it to work more closely with healthcare providers.
IQVIA™ (NYSE:IQV) today announced that Novo Nordisk, a global healthcare company with nearly a century of innovation and leadership in diabetes care, has selected IQVIA’s market-leading Orchestrated Customer Engagement platform for deployment across Novo Nordisk International Operations.
IQVIA™ (NYSE:IQV) announced today the launch of Informed Consent Form (ICF) Author, a SaaS eConsent tool for use in clinical trials.
Revenue $2,594 million, up 6.3 percent at constant currency and 5.2 percent reported
IQVIA today announced that the pharmaceuticals division of Roche (F. Hoffmann-La Roche Ltd) has selected IQVIA’s commercial technology suite for deployment across more than 100 markets.
IQVIA Holdings Inc. will announce its third-quarter 2018 financial results before the market opens on Monday, October 22, 2018.
IQVIA and Genomics England Launch the First Real-World Research Platform with Integrated Clinical and Genomic Data
IQVIA™ (NYSE:IQV) and Genomics England today announced a collaboration to develop a platform that will connect clinical and de-identified genomics data to accelerate treatment advancements for patients.
Medisafe, the leading medication management platform with over four and a half million registered users, released data today showing that hypertensive patients on the mobile health app, Medisafe, have a rate of therapy persistence almost 2.5 times or 136 percent that of a matched control cohort over a 12-month period, with the disparity increasing further over time.
Elite Pharmaceuticals, Inc. today reported positive topline results from pivotal bioequivalence studies conducted for an undisclosed immediate-release antibiotic generic product being co-developed with SunGen Pharma.
ARM Foundation for Cell and Gene Medicine releases Health Economic Impact Landscape Analysis led by IQVIA
The ARM Foundation for Cell and Gene Medicine (ARM Foundation) today released its first-of-its-kind Health Economic Impact Landscape Analysis of regenerative medicine advanced therapy.
Medytox Selects IQVIA’s Enterprise Quality Management Platform, Including SmartSolve®, for Quality and Compliance Management
IQVIA™ announced that the global biopharmaceutical company Medytox has selected IQVIA’s Enterprise Quality Management Solutions (EQMS) platform for quality and compliance management.
IQVIA (NYSE:IQV) today announced that Jon Resnick, IQVIA’s president, Real-World & Analytics Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
Revenue $2,567 million, up 9.0 percent reported and 7.7 percent at constant currency
IQVIA Holdings Inc. will announce its second-quarter 2018 financial results before the market opens on Tuesday, July 24, 2018.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
IQVIA (NYSE:IQV) announced today the launch of Virtual Research Solutions.